Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 972
countries
28
conditions
2 103

10 trials match your criteria

Relapsing-remitting multiple sclerosis

Recruiting

Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate

Multiple sclerosis+1

Not yet recruiting

Study of Lactobacillales and Lacidofil in Multiple Sclerosis Patients: Comparing Effectiveness of Probiotic Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab

Nervous system disorder+1

Not yet recruiting

Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:KYV-101

Multiple sclerosis relapse

Not yet recruiting

Study on Ofatumumab Levels in Breast Milk of Women with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ofatumumab

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Alemtuzumab

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Ofatumumab

Multiple sclerosis relapse

Not recruiting

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate

Multiple sclerosis relapse

Not recruiting

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Ofatumumab

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Ofatumumab

Multiple sclerosis+4

Not recruiting

Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.